| Oct 9 |
Atea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ...
|
| Oct 4 |
Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
| Sep 13 |
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus
|
| Sep 13 |
Atea stock drops as COVID-19 therapy fails in late-stage trial
|
| Sep 13 |
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
|
| Aug 28 |
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
|
| Aug 28 |
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway
|
| Aug 13 |
Atea rises after Morgan Stanley upgrade
|
| Aug 12 |
All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy
|
| Aug 12 |
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
|
